A phase-3 ready product that uses a proprietary platform for enhanced absorption of lipophilic drugs that effectively reduces triglycerides.

SC401 with the Advanced Lipid Technologies® (ALT®) Platform is an investigational drug designed to reduce triglycerides through increased bioavailability and lower dosing, which may potentially reduce comorbidities associated with higher triglycerides.

ALT® Technology Is A Proprietary Micelle-Based Formulation That Has Been Clinically Demonstrated To:

Create engineered micelles, allowing for improved lipid absorption

Enhance bioavailability of lipid and lipophilic materials

Reduce triglycerides in 14 days

Allow for lower dosing – 42.5% vs. competitors

Reduce the food effect

Allow for smaller, easier to swallow SoftGel than currently available treatment